Detail akcie Corb Phrm Hldgs Rg online

Business Summary: Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Corbus Pharmaceuticals Holdings Inc revenues was not reported. Net loss increased 89% to $58M. Higher net loss reflects Research and development - Balancing val increase from $22.7M to $51.2M (expense), R&D Expense - Tax Credit decrease of 71% to $1.2M (income), General and administrative - Balancing v increase of 17% to $10.4M (expense).